Fragile X Treatment Trials
The Greenwood Genetic Center has been selected to participate in the following treatment trial for adults with Fragile X syndrome.
Sponsored by Novartis Pharmaceutical Company.
GGC is now recruiting male and female adults, ages 18-45 years, with a confirmed diagnosis of Fragile X syndrome to test how well an investigational medication works to treat behavioral symptoms associated with Fragile X syndrome. Data from this study will be used to support the registration of the investigational medication in this population and to guide future development of the medication in younger patients with Fragile X syndrome.
The study will last for 20 weeks and the patient will either receive the investigational medication or a placebo (sugar pill). Since the study is double-blinded, neither the patient nor the doctor will know which pill the patient is taking. All evaluations and study medications are provided at no cost to the patients. All visits (9 in total) will take place in Greenwood, SC at the main campus of the Greenwood Genetic Center. Visits are expected to last one full day. Families who participate in the study will be reimbursed for their travel expenses.
Patients must meet inclusion criteria, which will be assessed during a screening visit, before enrolling in the study. Patients participating in the methylation study of Fragile X are also eligible to participate in this treatment study.